<PAGE> 1
Amended
Form 8-K
CURRENT REPORT
Pursuant to Section 13 of 15 (d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2000
Hemispherx Biopharma, Inc.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 027072 2-0845822
---------- -------- -----------
(State or other (Commission (I.R.S.Employer
jurisdiction of File Number) Identification No.)
incorporation)
1617 JFK Blvd, #660, Philadelphia, Pennsylvania 19104
------------------------------------------------ ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (215) 988-0080
N/A
-------------------------------------------------------------
Former name or former address, if changed since last report)
<PAGE> 2
Item 4. Changes in Registrant's Certifying Accountant.
On May 3, 2000, KPMG LLP ("KPMG") resigned from
the client-auditor relationship with the Registrant. On May
3, 2000, pursuant to the prior decision of Registrant's Board
and Audit Committee of the Board of Directors to seek and
retain the services of an independent accounting firm other
than KPMG, Registrant accepted the resignation of KPMG and
confirmed that the client-auditor relationship with the
Company had ceased.
KPMG's reports on the financial statements of
Registrant for the fiscal years ended December 31, 1998, and
December 31, 1999, did not contain any adverse opinion or any
disclaimer of opinion and were not qualified or modified as
to uncertainty, audit scope or accounting principles.
During the Registrant's two most recent fiscal
years ending December 31, 1998, and December 31, 1999, and
the subsequent interim period through May 3, 2000, there were
no "reportable events" as described in Items 304(a)(l)(iv)
and (v) of Regulation S-K and no disagreements between the
Registrant and KPMG on any matter of accounting principles or
practice, financial statement disclosure or auditing scope of
procedure which, if not resolved to the satisfaction of KPMG
would have caused KPMG to make a reference to the subject
matter thereof in connection with its reports.
On June 5, 2000, Registrant engaged the services
of BDO Seidman, LLP as the Registrant's Independent
Accountants. As the Independent Accountants, BDO Seidman,
LLP will audit the Consolidated Financial Statements and
provide other professional services as may be required by the
Registrant.
The Registrant's Board of Directors, with the
approval of Registrant's audit committee, authorized the
Company to retain the services of BDO Seidman, LLP.
Incorporated by reference are Form 8-Ks filed by
the Registrant with the Securities and Exchange Commission on
May 10, 2000, and as amended on May 18 and June 6, 2000, to
include the response of former Registrant's Independent
Accountants.
The Registrant has requested that KPMG furnish it
with a letter addressed to the Securities and Exchange
Commission stating whether or not it agrees with the above
statements. A copy of such letter shall be filed as exhibit
(16) to a subsequent form 8K within 10 business days after
the date of filing this form 8K.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned,
thereunto duly authorized.
HEMISPHERX BIOPHARMA,
INC.
Dated: July 12, 2000 By: / s / W. A. Carter, M.D.
---------------------------
W. A. Carter, M.D.
Chairman/CEO/President
